Clinical Efficacy of Heparin Fractions: Issues and Answers

References

• Poter J., Jick H. Drug-related deaths among medical inpatients. JAMA 1977; 237: 879
   PubMed Web of Science ®Google Scholar
• Verstraete M. Unresolved questions with heparin. Triangle-Sandoz J. Med. Sci. 1984; 23: 49
   Google Scholar
• George P. M., Travis J., Vissers M. C. M., Winterbourn C. C., Carrell R. W. A genetically engineered mutant of alpha 1, antitrypsin protects connective tissue from neutrophile damage and may be useful in lung disease. Lancet 1984; 2: 1426
   PubMed Web of Science ®Google Scholar
• Carrell R. Therapy by instant evolution. Nature (London) 1984; 312: 14
   PubMed Web of Science ®Google Scholar
• Thomas D. P., Curtis A. D., Barrowcliffe T. W. A collaborative study designed to establish the 4th international standard for heparin. Thromb. Haemost. 1984; 52: 148
   PubMed Web of Science ®Google Scholar
• Choay J., Lormeau J. C., Petitou M., Sinay P., Fareed J. Structural studies on a biologically active hexasaccharide obtained from heparin. Ann. N. Y. Acad. Sci. 1981; 370: 644
   PubMedGoogle Scholar
• Bjork J., Lindahl U. Mechanison of the anticoagulant action of heparin. Mol. Cell. Biochem. 1982; 48: 161
   PubMed Web of Science ®Google Scholar
• Ofosu F. A., Modi G., Cerksus A., Hirsh J., Blajchman M. A. Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma. Thromb. Res. 1982; 28: 487
   PubMed Web of Science ®Google Scholar
• Carter C. J., Kelton J. G., Hirsh J., Cerskua A., Santos A. V., Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239
   PubMed Web of Science ®Google Scholar
• Cade J. F., Buchanan M. R., Boneu B., Ockelford P., Carter C. J., Cerskus A. L., Hirsh J. A comparison of the antithrombotic and hemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb. Res. 1984; 35: 613
   PubMed Web of Science ®Google Scholar
• Saba H. I., Saba S. R., Morelli B. A. Effect of heparin on platelet aggregation. Am. J. Hematol. 1984; 17: 295
   PubMed Web of Science ®Google Scholar
• Castellot J. J., Jr., Favreau L. V., Rosenberg R. D., Karnovsky M. J. Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin. Possible role of a platelet derived endoglycosidase. J. Biol. Chem. 1982; 257: 11256
   PubMed Web of Science ®Google Scholar
• Hoover R. J., Rosenberg R. D., Hoering W., Karnovsky M. J. Inhibition of rat arterial smooth muscle cell proliferation by heparin. In-vitro studies. Circ. Res. 1980; 47: 578
   PubMed Web of Science ®Google Scholar
• Ljungberg B., Blomback M., Johnsson H., Kistner S., Lins L.-E., Wilhelmsson S. A low molecular weight heparin fraction as anticoagulant during haemodialysis. Thromb. Haemost. 1983; 50: 184, (Abstr. 0566)
   Web of Science ®Google Scholar
• Henry I., ten Cate J. W., Bronswijk H., ten Cate H., Surachno S., Wilmink J., Ockelford P. Use of a new heparinoid as anticoagulant during acute haemodialysis of patients without bleeding complications. Lancet 1983; 1: 890
   PubMed Web of Science ®Google Scholar
• Messmore H., Daugirdas J., Ing T., Fareed J., Griffin B., Corey J., Zuckerman L. Blood 1984; 64: 265A, (Abstr. 970)
   Google Scholar
• Barlow G. H. Molecular weight distribution determination on heparin samples. Thromb. Res. 1983; 31: 513
   PubMed Web of Science ®Google Scholar
• Rosenberg R. D. Heparin-antithrombin system. Hemostasis and Thrombosis, R. W. Coleman, J. Hirsh, V. Marder, E. Salzman. Lippincott J. B., Philadelphia 1983; 962
   Google Scholar
• Scott C. F., Schapira M., Colman R. Effect of heparin on the inactivation rate of human Factor XIa by antithrombin-III. Blood 1982; 60: 940
   PubMed Web of Science ®Google Scholar
• Ofosu F. A., Blajchman M. A., Hirsh J. The inhibition of heparin of the intrinsic pathway of activation of Factor X in the absence of antithrombin III. Thromb. Res. 1980; 20: 391
   PubMed Web of Science ®Google Scholar
• Saba H. I., Saba S. R., Morelli G. A. Effect of heparin on platelet aggregation. Am. J. Hematol. 1984; 17: 295
   PubMed Web of Science ®Google Scholar
• Tollefson D. M., Blank M. K. Detection of a new heparin-dependent inhibitor of thrombin in human plasma. J. Clin. Invest. 1981; 68: 589
   PubMed Web of Science ®Google Scholar
• Vairel E., Bronty-Boye J., Doutremepuich C., Toulemonde F., March N., Gaffney P. Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis. Thromb. Res. 1983; 30: 219
   PubMed Web of Science ®Google Scholar
• Thomas D. P., Heparin. low molecular weight heparin and heparin analogues. Br. J. Haematol. 1984; 58: 385
   PubMed Web of Science ®Google Scholar
• Oosta G., Gardner W., Beeler L., Rosenberg R. Multiple functional domains of the heparin molecule. Proc. Natl. Acad Sci. U.S.A. 1981; 78: 829
   PubMed Web of Science ®Google Scholar
• Graham D. T., Pomeroy A. R. Relative activities of heparin fractions obtained by gel chromatography. Thromb. Haemost. 1979; 42: 1598
   PubMed Web of Science ®Google Scholar
• Cifonelli J. R. Nitrous acid depolymerization of glycosaminoglycans. Methods Carbohydr. Chem. 1976; 7: 139
   Google Scholar
• Linker A., Hovingh P. The enzymatic degradation of heparin and heparitin sulfate. The fractionization of a crude heparinase from flavobacterium. J. Biol. Chem. 1965; 240: 3724
   PubMed Web of Science ®Google Scholar
• Linhardt R., Grant A., Cooney C., Langer R. Differential anticoagulant activity of heparin fragments prepared using microbial heparinase. J. Biol. Chem. 1982; 267: 7310
   Google Scholar
• Sugisaka N., Petrocek F. Rapid molecular size characterization of heparins by high pressure liquid chromatography. Fed. Proc. 1977; 36: 89
   PubMedGoogle Scholar
• Alach M., Michaud A., Balian J.-L., Lefebvre M., Woler M., Fourtillan J. A new low molecular weight heparin derivative. Thromb. Res. 1983; 31: 611
   Web of Science ®Google Scholar
• Gundry S., Klein M., Drongowski R., Kirsh M. Clinical evaluation of a new rapid heparin assay using the dye Azure. A. Am. J. Surg. 1984; 148: 191
   PubMed Web of Science ®Google Scholar
• Barzu T., Molko P., Tobelem G., Petitou M., Caen J. Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture. Nouv. Rev. Fr. Hematol. 1984; 26: 243
   PubMedGoogle Scholar
• Watz D., Hung G.-L. In vivo studies on the binding of heparin and its fractions with platelet factor 4. Sem. Thromb. Hemost. 1985; II: 40
   Google Scholar
• Lijnen H., Van Hoef B., Collen D. Histidine-rich glycoprotein modulates the anticoagulant activity of heparin in human plasma. Thromb. Haemost. 1984; 51: 266
   PubMed Web of Science ®Google Scholar
• Van de Water L. S., Schroeder S., Crenshaw E. B., Hyrnes R. O. Phagocytosis of gelatinlatex particles by a murine macrophage line is dependent on fibronectin and heparin. J. Cell. Biol. 1981; 90: 32
   PubMed Web of Science ®Google Scholar
• Sinay P., Jacquinet J. C., Petitou M., Duchoussoy P., Lederman I., Choay J. Total synthesis of a heparin pentasaccharide fragment having high affinity for antithrombin III. Carbohydr. Res. 1984; 132: C5
   Web of Science ®Google Scholar
• Tollefsen D. M., Pestka C. A., Monafo W. J. Activation of heparin cofactor II by dermatan sulfate. J. Biol. Chem. 1983; 258: 6713
   PubMed Web of Science ®Google Scholar
• Buchanan M., Boneau B., Ofosu F., Hirsh J. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Blood 1985; 65: 198
   PubMed Web of Science ®Google Scholar
• Meuleman D. G., Hobbelen P. M. J., van Dedem G., Moelker H. C. T. A novel antithrombotic heparinoid (org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models. Thromb. Res. 1982; 27: 353
   PubMed Web of Science ®Google Scholar
• Scully M. F., Kakkar V. V. Identification of heparin cofactor II as the principle plasma cofactor for the antithrombin activity of pentosan polysulfate (SP54). Thromb. Res. 1984; 36: 187
   PubMed Web of Science ®Google Scholar
• Scully M. F., Kumudini M., Weerasinghe V., Ellis V., Djazaeri B., Kakkar V. V. Anticoagulant and antiheparin activities of a pentosan polysulfate. Thromb. Res. 1983; 31: 87
   PubMed Web of Science ®Google Scholar
• Merten R. E., Thomas D. P., Hovercroft S. J., Barrowcliffe T. W., Lindahl V. High and low affinity heparin compared with unfractionated heparin as antithrombotic drugs. Thromb. Haemost. 1984; 51: 254
   PubMed Web of Science ®Google Scholar
• Ockelford P. A., Carter C. J., Cerskus A., Smith C. A., Hirsh J. Comparison of the in vivo hemorrhagic and antithrombotic effects of a low antithrombin III affinity heparin fraction. Thromb. Res. 1982; 27: 679
   PubMed Web of Science ®Google Scholar
• Hirsh J. Heparin induced bleeding. Nouv. Rev. Fr. Hematol. 1984; 26: 261
   PubMedGoogle Scholar
• Cade J. F., Buchanan M. R., Boneu B., Ockelford P., Carter C. J., Cerskus A. L., Hirsh J. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions. The influence of the method of preparation. Thromb. Res. 1984; 35: 613
   PubMed Web of Science ®Google Scholar
• Schmitz-Huebner U., Friese G., Reers B., Rueschemeyer C., Scherer R., Schoenleben K., Van de Loo J. Thromb. Haemost. 1983; 50: 10
   Google Scholar
• Ockelford P., Carter C. J., Mitchell L., Hirsh J. Discordance between the anti-Xa activity and the antithrombotic activity of an ultra-low molecular weight heparin fraction. Thromb. Res. 1982; 28: 401
   PubMed Web of Science ®Google Scholar
• Barrowcliffe T. W., Merton R. E., Havercroft S. J., Thunberg L., Lindahl U., Thomas D. P. Low-affinity heparin potentiates the action of high affinity heparin oligosaccharides. Thromb. Res. 1984; 34: 125
   PubMed Web of Science ®Google Scholar
• King D. J., Kelton J. G. Heparin-associated thrombocytopenia. Ann. Int. Med. 1984; 100: 535
   PubMed Web of Science ®Google Scholar
• Messmore H., Fareed J., Corey J., Griffin B., Miller A. In vitro assessment of low molecular weight heparin in patients with thrombocytopenia induced by standard heparin. Blood 1984; 64: 238a, (Abstr. 864)
   Google Scholar
• Green D., Harris K., Reynolds N., Roberts M., Patterson R. Heparin immune thrombocytopenia: evidence for a heparin platelet complex as the antigenic determinant. J. Lab. Clin. Med. 1978; 91: 167
   PubMed Web of Science ®Google Scholar
• Harenburg J., Zimmerman R., Schwarz F., Kubler W. Treatment of heparin-induced thrombocytopenia with thrombosis by a new heparinoid. Lancet 1983; 1: 986
   Web of Science ®Google Scholar
• Messmore H., Fareed J., Parvey Z., Kniffen J., Squillaci G., Hixon B., Moncivaiz E. Studies on the mechanism of heparin induced thrombocytopenia. Thromb. Haemost. 1981; 46: 215, (Abstr. 0679)
   Web of Science ®Google Scholar
• Messmore H., Fareed J., Parvey Z., Zuckerman L. The therapeutic usefulness of heparin fractions in patients with heparin-induced thrombocytopenia, Pharmuka Symposium on Heparin, ParisFrance, June, 1983, in press
   Google Scholar
• Messmore H. Clinical use of heparin fractions, fragments and heparinoids. Sem. Thromb. Hemost. 1985; II: 212
   Google Scholar
• Kelton J., Sheridan D., Brain H., Powers P., Turple A., Carter C. Clinical usefulness of testing for a heparin-dependent platelet-aggrevating factor in patients with suspected heparin-associated thrombocytopenia. J. Lab. Clin. Med. 1984; 103: 606
   PubMed Web of Science ®Google Scholar
• Sheridan D., Carter C., Kelton J. G. A diagnostic test for heparin induced thrombocytopenia. Blood 1984; 64: 240a, (Abstr. 872)
   Google Scholar
• March N., Goffrey P. The effect of pentosan polysulfate on the fibrinolytic system of man. Thromb. Haemost. 1983; 50(1): 83, (Abstr. 0246)
   Web of Science ®Google Scholar
• Comp P. C. Heparin-protein C interaction. Nouv. Rev. Fr. Hematol. 1984; 26: 239
   PubMedGoogle Scholar
• Hiebert L. M., Jaques L. B. The observation of heparin on endothelium after injection. Thromb. Res. 1976; 8: 195
   PubMed Web of Science ®Google Scholar
• Quick A., Shanberge M., Stefanini M. The effect of heparin on platelets in vivo. J. Lab. Clin. Med. 1948; 33: 1424
   PubMed Web of Science ®Google Scholar
• Gollub S., Ulin A. W. Heparin induced thrombocytopenia in man. J. Lab. Clin. Med. 1962; 59: 430
   PubMed Web of Science ®Google Scholar
• Salzman E. W., Rosenberg R. D., Smith M. H., Linden J. N., Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J. Clin. Invest. 1980; 65: 64
   PubMed Web of Science ®Google Scholar
• Saba H., Saba S., Morelli G. Effect of heparin on platelet aggregation. Am. J. Hematol. 1984; 17: 295
   PubMed Web of Science ®Google Scholar
• Barrett P., Butler K., Morley J., Page C., Paul W., White A. Inhibition by heparin of platelet accumulation in-vivo. Thromb. Haemost. 1984; 51: 366
   PubMed Web of Science ®Google Scholar
• Shanberge J. N., Kambayashi J., Nakagawa M. The interaction of platelets with a tritiumlabelled heparin. Thromb. Res. 1976; 9: 595
   PubMed Web of Science ®Google Scholar
• Godstad G., Solum N., Krutnes M.-B. Heparin-binding platelet proteins demonstrated by crossed affinity immunoelectrophoresis. Br. J. Haematol. 1983; 53: 563
   PubMed Web of Science ®Google Scholar
• Dunn F., Soria J., Soria C., Thomaldis A., Tobelem G., Caen J. Fibrinogen binding on human platelets. Influence of different heparins and of pentosan polysulfate. Thromb. Res. 1983; 29: 141
   PubMed Web of Science ®Google Scholar
• Eika C. The platelet-aggregating effect of eight commercial heparins. Scand. J. Haematol. 1972; 9: 480
   PubMedGoogle Scholar
• Thomson C., Forbes C., Prentice C. The potentiation of platelet aggregation and adhesion by heparin in vivo and in vitro. Clin. Sci. Mol. Med. 1973; 45: 485
   PubMedGoogle Scholar
• Johnson R., Lazarus K., Henry D. Heparin induced thrombocytopenia; a prospective study. Am. J. Hermot. 1984; 17: 349
   PubMed Web of Science ®Google Scholar
• Fiedel B. Platelet againist synergism by the acute phase reactant C-reactive protein. Blood 1985; 65: 264
   PubMed Web of Science ®Google Scholar
• Walz D. A., Hung G.-L. In vivo studies on the binding of heparin and its fractions with platelet factor 4. Sem. Thromb. Hemost. 1985; 11: 40
   PubMed Web of Science ®Google Scholar
• Barrowcliffe T. W., Johnson E. A., Eggleton A., Kemball-Cook G., Thomas D. P. Anti-coagulant activities of high and low molecular weight heparin fractions. Br. J. Haematol. 1979; 41: 573
   PubMed Web of Science ®Google Scholar
• Jansen P. A., Moake J. L. Aspirin prevents in vivo platelet aggregation, thrombocytopenia and thrombosis induced by heparin. Br. J. Haematol. 1983; 53: 166
   PubMedGoogle Scholar
• Avioli L. V. Heparin induced osteopenia: an appraisal. Adv. Exp. Med. Biol. 1975; 52: 375
   PubMedGoogle Scholar
• DeSwiet M., Ward P. D., Fidler J., Horsman A., Katz D., Letzky E., Peacock M., Wise P. H. Prolonged heparin therapy in pregnancy causes bone demineralization. Br J. Obstetr. Gynecol. 1983; 90: 1129
   PubMedGoogle Scholar
• Holzgreve W., Carey J., Hall B. Warfarin-induced fetal abnormalities. Lancet 1976; II: 914
   Google Scholar
• Andersson G., Fagrell B., Holmgren K., Johnsson H., Ljundberg B., Nillson E., Wilhelmsson S., Zetterquist S. Subcutaneous administration of heparin: a randomized comparison with intravenous heparin for deep vein thrombosis. Thromb. Res. 1982; 27: 631
   PubMed Web of Science ®Google Scholar
• Kakkar V., Djazaeri B., Pok J., Fletcher M., Scully M., Westivich J. Low molecular weight heparin and prevention of postoperative deep-vein thrombosis. Br. Med. J. 1982; 284: 375
   PubMed Web of Science ®Google Scholar
• Mahadoo J., Wright C. J. Intrapulmonary heparin as a prospective anticoagulant regimen. Perspectives in Hermastosis, J. Fareed, H. Messmore, J. Fenton, E. Brinkhous. Pergamon Press, New York 1981; 233
   Google Scholar
• Fareed J., Kumar A., Walenga J., Emanuele R., Williamson K., Hoppensteadt D. Antithrombotic actions and pharmacokinetics of heparin fractions and fragments. Nouv. Rev. Fr. Hematol. 1984; 26: 267
   PubMedGoogle Scholar
• Lasker S. Low molecular weight heparin-like preparations with oral activity. Sem. Thromb. Hemost. 1985; 11: 37
   PubMed Web of Science ®Google Scholar
• Epstein M. The luveen shunt for ascites and hepotorenal syndrome. N. Engl. J. Med. 1980; 302: 628
   PubMed Web of Science ®Google Scholar
• Bick R. L. Alterations of hemostasis associated with cardiopulmonary bypass: pathophysiology, prevention, diagnosis and management. Sem. Thromb. Hemost. 1976; 3: 59
   PubMedGoogle Scholar
• Harker L., Malpass T., Bronson H., Hessel E., Slichter S. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha granule release. Blood 1980; 56: 824
   PubMed Web of Science ®Google Scholar
• Fiser W., Read R., Wright F., Vecchio T. A randomized study of beef lung and pork mucosal heparin in cardiac surgery. Ann. Thorac. Surg. 1983; 35: 615
   PubMed Web of Science ®Google Scholar
• Gott V. L. Wall-bonded heparin—historical background and current clinical applications. Adv. Exp. Med. Biol. 1975; 52: 351
   PubMedGoogle Scholar
• Lam L., Silbert J., Rosenberg R. The separation of active and inactive forms of heparin. Biochem. Biophys. Res. Commun. 1976; 78: 831
   Google Scholar
• Kumar A., Fareed J., Walenga J., Hoppensteadt D., Williamson K. Validity of animal models of thrombosis in the assessment of the antithrombotic activity of heparin fractions. Fed. Proc. 1984; 43: 605
   Google Scholar
• Roncaglioni M., Bertele V., de Gaetano G., Donati M. Lack of interaction of heparin with ADP and prostacyclin on rat platelets. Thromb. Res. 1983; 31: 397
   PubMed Web of Science ®Google Scholar
• Rosenberg R., Rosenberg J. Natural anticoagulant mechanisms. J. Clin. Invest. 1984; 74: 1
   PubMed Web of Science ®Google Scholar
• Fareed J., Walenga J., Williamson K., Emanuele R., Kumar A., Hoppensteadt D. Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments. Sem. Thromb. Hemost. 1985; 11: 56
   PubMed Web of Science ®Google Scholar
• Tiffany M., Penner J. Effect of heparin and other polyanions on collagen induced platelet aggregation. J. Cell. Biol. 1981; 205A: 1131
   Google Scholar
• Umetsu T., Sanai K. Effect of 1-methyl-3-mercapto-5-(3-pyridyl) imidazole (KC-6141), an anti-aggregating compound on experimental thrombosis in rats. Thromb. Haemost. 1978; 39: 74
   PubMed Web of Science ®Google Scholar
• Carter C., Kelton J., Hirsh J., Gent M. Relationships between the antithrombotic and anticoagulant effects of low molecular weight heparin. Thromb. Res. 1981; 21: 169
   PubMedGoogle Scholar
• Boneu B., Buchanan M., Cade J., Ryn J., Hirsh J. Effects of low molecular weight heparin fractions on inhibition of thrombus growth. Circulation 1984; 70((Suppl. II))361, (Abstr. 1444)
   Google Scholar
• Woods H., Ash G., Weston M., Bunting S., Moncada S., Vane J. Prostacyclin can replace heparin in haemodialysis in dogs. Lancet 1983; II: 1374
   Google Scholar
• Gouvalt-Heilman M., Huet Y., Contant G., Payen D., Block G., Rapin M. Cardiopulmonary bypass with a low-molecular-weight heparin fraction. Lancet 1983; II: 1374
   Google Scholar
• Andrew M., Buchanan M., Ofosu F., Jeffries A., Hirsh J. Altered fetal lamb coagulation after administration of low molecular weight heparin in the ewe. Circulation 1984; 70(Suppl II)362, (Abstr. 1446)
   Google Scholar
• Esquivel C., Bergqvist Bjorck C.-G., Nilsson B. Comparison between commercial heparin, low molecular weight heparin and pentosan polysulfate in hemostasis and platelets in vivo. Thromb. Res. 1982; 28: 389
   PubMed Web of Science ®Google Scholar
• Kakkar V. Prevention of post-operative venous thromboembolism by a new low molecular weight heparin fraction. Nouv. Rev. Fr. Hematol. 1984; 26: 277
   PubMedGoogle Scholar
• Schmitz-Huebner V., Bunte H., Freise G., Reers B., Ruschemeyer C., Scherer R., Schulte H. Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis. Klin. Wochenschr. 1984; 62: 349
   PubMedGoogle Scholar
• Schrader J., Rieger J., Muschen H., Stibbe W., Kostering H., Kramer P., Scheler F. Anwendung von niedermolecularem heparin bei Hemodialysepatienten. Klin. Wochenschr. 1985; 63: 49
   PubMedGoogle Scholar
• Powers P., Kelton J., Carter C. Studies on the frequency of heparin-associated thrombocytopenia. Thromb. Res. 1984; 33: 439
   PubMed Web of Science ®Google Scholar
• Malcolm I., Wegmore T., Steinbrecher V. Heparin-associated thrombocytopenia: low frequency in 104 patients treated with heparin of intestinal mucosal origin. Can. Med. Assoc. J. 1979; 120: 1086
   PubMed Web of Science ®Google Scholar
• Fratantoni J., Pollet R., Gralnick H. Heparin-induced thrombocytopenia: confirmation of diagnosis with in vitro methods. Blood 1975; 45: 395
   PubMed Web of Science ®Google Scholar
• Stead R., Schafer A., Rosenberg R., Handin R., Josa M., Khuri S. Heterogeneity of heparin lots associated with thrombocytopenia and thromboembolism. Am. J. Med. 1984; 77: 185
   PubMed Web of Science ®Google Scholar
• Chong B., Pitney W., Castaldi P. Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis and platelet aggregation. Lancet 1982; II: 1246
   Google Scholar
• Horrellou M., Conard J., Lacrubier C., Sarmama M. Persistent heparin-induced thrombocytopenia despite therapy with low molecular weight heparin. Presse Med. 1983; 12: 643
   Web of Science ®Google Scholar
• Leroy J., Delahousse B., Gueroi C., Leclerc M., Toulemonde F. Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY216 Choay):34 cases. Symposium on heparin, heparin fractions and fragments, Loyola University Stritch School of Medicine, Maywood, Nov., 111984
   Google Scholar
• Messmore H., Fareed J., Parvey Z., Kniffen J., Squillaci G., Hixan B., Moncivaiz E. Studies on the mechanisms of heparin-induced thrombocytopenia. Thromb. Haemost. 1981; 46: 215
   Web of Science ®Google Scholar
• Huisse M., Guillin M., Berzeaud A., Toulemondi F., Kitzis M., Andreassian B. Heparin associated thrombocytopenia. In vitro effects of different molecular weight fractions. Thromb. Res. 1982; 27: 485
   PubMed Web of Science ®Google Scholar
• Messmore H., Fareed J., Corey J., Griffin B., Miller A., Zuckerman L., Parvey Z., Seghatchiari J. In-vitro assessment of low molecular weight heparin in patients with thrombocytopenia induced by standard heparin. Blood 1984; 64((Suppl. 1))238a, (Abstr. 864)
   Google Scholar
• Doyle D., Belbeck L., McDonald S., Turpie A., Gunstensen J., Carter C., Fedryna C., Pineau S., Welber C., Russett J., Wood H., Hirsch J. Comparison of low-molecular weight heparin (CY222) with standard heparin for cardiopulmonary bypass in dogs. Blood 1983; 62: 229a, (Abstr. 1102)
   Google Scholar
• Fernandez F., Van Ryn S., Ofosu F. A., Hirsh J., Buchanan M. R. The hemorrhagic and antithrombotic effects of dermatan sulfate. Abstract Proc. Int. Cong. Hermost. and Thrombosis. July, 1985, in press
   Google Scholar
• Messmore H. L., submitted
   Google Scholar